Published in Biol Psychiatry on August 02, 2007
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct (2008) 6.32
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry (2014) 1.54
The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology (2013) 1.51
Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience (2009) 1.49
Neuroimaging of the periaqueductal gray: state of the field. Neuroimage (2011) 1.49
Affective cognition and its disruption in mood disorders. Neuropsychopharmacology (2010) 1.47
Cytology and receptor architecture of human anterior cingulate cortex. J Comp Neurol (2008) 1.31
Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry (2013) 1.07
Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J Neurosci (2009) 1.04
Major depressive disorder and alterations in insular cortical activity: a review of current functional magnetic imaging research. Front Hum Neurosci (2012) 1.03
Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse (2009) 0.99
Retracted Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis (2011) 0.98
Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play. Mol Psychiatry (2013) 0.93
Endogenous opioids mediate left dorsolateral prefrontal cortex rTMS-induced analgesia. Pain (2012) 0.92
Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology (2008) 0.92
Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) (2010) 0.92
Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage (2009) 0.90
Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins. Transl Psychiatry (2011) 0.89
Long-term ovariectomy decreases serotonin neuron number and gene expression in free ranging macaques. Neuroscience (2011) 0.89
Multi-scale motility amplitude associated with suicidal thoughts in major depression. PLoS One (2012) 0.87
Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) (2009) 0.87
Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry (2010) 0.87
Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry (2014) 0.86
Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol (2010) 0.85
Effects of genetic and early environmental risk factors for depression on serotonin transporter expression and methylation profiles. Transl Psychiatry (2014) 0.85
The relation of developmental changes in brain serotonin transporter (5HTT) and 5HT1A receptor binding to emotional behavior in female rhesus monkeys: effects of social status and 5HTT genotype. Neuroscience (2012) 0.84
fMRI responses to emotional faces in children and adolescents at genetic risk for psychiatric illness share some of the features of depression. J Affect Disord (2012) 0.84
Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin Psychopharmacol Neurosci (2014) 0.84
Meta-analysis of molecular imaging of serotonin transporters in major depression. J Cereb Blood Flow Metab (2014) 0.84
Surface-based regional homogeneity in first-episode, drug-naïve major depression: a resting-state FMRI study. Biomed Res Int (2014) 0.83
A Pontine Region is a Neural Correlate of the Human Affective Processing Network. EBioMedicine (2015) 0.82
Pons to Posterior Cingulate Functional Projections Predict Affective Processing Changes in the Elderly Following Eight Weeks of Meditation Training. EBioMedicine (2016) 0.82
A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study. Mol Psychiatry (2011) 0.81
Molecular imaging in patients with mood disorders: a review of PET findings. Eur J Nucl Med Mol Imaging (2011) 0.81
Serotonin transporter binding after recovery from bulimia nervosa. Int J Eat Disord (2011) 0.81
Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci (2013) 0.79
Neurotransmission and bipolar disorder: a systematic family-based association study. Am J Med Genet B Neuropsychiatr Genet (2008) 0.79
A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. Depress Res Treat (2014) 0.79
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. Am J Psychiatry (2017) 0.78
Case-control resting-state fMRI study of brain functioning among adolescents with first-episode major depressive disorder. Shanghai Arch Psychiatry (2014) 0.77
Functional neuroimaging in geriatric depression. Psychiatr Clin North Am (2011) 0.77
Intuition, insight, and the right hemisphere: Emergence of higher sociocognitive functions. Psychol Res Behav Manag (2010) 0.77
Lithium induces ER stress and N-glycan modification in galactose-grown Jurkat cells. PLoS One (2013) 0.77
Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus. Psychopharmacology (Berl) (2014) 0.76
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). Epilepsy Behav (2013) 0.76
Positron emission tomography molecular imaging in late-life depression. J Geriatr Psychiatry Neurol (2014) 0.76
Incongruent reduction of serotonin transporter associated with suicide attempts in patients with major depressive disorder: a positron emission tomography study with 4-[18F]-ADAM. Int J Neuropsychopharmacol (2014) 0.76
Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity. Front Psychiatry (2013) 0.76
Can the Lateral Habenula Crack the Serotonin Code? Front Synaptic Neurosci (2016) 0.75
Modulation of serotonin transporter function by kappa-opioid receptor ligands. Neuropharmacology (2016) 0.75
Positron emission tomography quantification of serotonin transporter binding in medication-free bipolar disorder. Synapse (2015) 0.75
High fat diet decreases beneficial effects of estrogen on serotonin-related gene expression in marmosets. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.75
123I-ADAM SPET imaging of serotonin transporter in patients with epilepsy and comorbid depression. BMC Neurol (2013) 0.75
Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM. Int J Neuropsychopharmacol (2015) 0.75
Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian J Psychiatry (2017) 0.75
Advances of Molecular Imaging in Epilepsy. Curr Neurol Neurosci Rep (2016) 0.75
Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression. Neuroscience (2017) 0.75
A positron emission tomography study of the serotonergic system in relation to anxiety in depression. Eur Neuropsychopharmacol (2017) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry (2003) 6.93
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry (2003) 6.52
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Defining clinical phenotypes of juvenile mania. Am J Psychiatry (2003) 5.49
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Psychobiology and molecular genetics of resilience. Nat Rev Neurosci (2009) 3.71
Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2007) 3.15
Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry (2007) 3.10
The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol (2005) 3.09
Publication bias and the efficacy of antidepressants. Am J Psychiatry (2009) 3.05
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
Adolescent immaturity in attention-related brain engagement to emotional facial expressions. Neuroimage (2003) 2.98
Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry (2006) 2.90
Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci (2011) 2.76
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53
MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry (2003) 2.51
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci (2006) 2.40
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry (2007) 2.25
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med (2006) 2.20
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry (2003) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Neurobiology of resilience. Nat Neurosci (2012) 2.13
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Attention bias to threat in maltreated children: implications for vulnerability to stress-related psychopathology. Am J Psychiatry (2005) 2.08
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med (2005) 1.99
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology (2003) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. J Natl Med Assoc (2006) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry (2002) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Trauma, resilience, and recovery in a high-risk African-American population. Am J Psychiatry (2008) 1.89
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry (2004) 1.85
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry (2004) 1.70
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Increased amygdala activity during successful memory encoding in adolescent major depressive disorder: An FMRI study. Biol Psychiatry (2006) 1.68
Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA (2003) 1.67
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry (2002) 1.65
An overview of posttraumatic stress disorder in African Americans. J Clin Psychol (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann N Y Acad Sci (2006) 1.62
Enduring mental health morbidity and social function impairment in world trade center rescue, recovery, and cleanup workers: the psychological dimension of an environmental health disaster. Environ Health Perspect (2008) 1.62
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Deficits in social cognition and response flexibility in pediatric bipolar disorder. Am J Psychiatry (2005) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry (2003) 1.61
Procedure guideline for brain perfusion SPECT using (99m)Tc radiopharmaceuticals 3.0. J Nucl Med Technol (2009) 1.57
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57